Nevertheless, although the sample size was small due to the limited use of SGLT2 inhibitors in this study population, it is worth noting that in our data, as shown in Table 3, there was no progression of renal disease in any of the patients who received SGLT2 inhibitors. Here, SLC5A2 is linked to kidney disorder.